MNKD
$2.73
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary ...
Recent News
How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts
MannKind’s fair value estimate has been trimmed from US$9.61 to US$7.50, a roughly 22% cut that sets a more conservative anchor for the stock. This reset lines up with a split analyst backdrop, where some see upside tied to the broader product portfolio, while others focus on risks to Tyvaso DPI royalties and 2026 execution. As you read on, you will see how these moving pieces shape the evolving MannKind story and what you might watch next. Analyst Price Targets don't always capture the full...
MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...
MannKind Corp (MNKD) reports a 46% revenue increase and outlines future growth strategies amid challenges in the pulmonary market.
MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets
MannKind Corporation (NASDAQ:MNKD) is among the best NASDAQ penny stocks to buy according to analysts. On 26 February, MannKind Corporation (NASDAQ:MNKD) shared its plans at the Oppenheimer healthcare conference. The company said it expects strong growth from its main products. These include Afrezza for children, the FUROSCIX autoinjector, and a new drug program, MNKD-201, for […]
MannKind at Oppenheimer: 2025 Revenue Jumps 46%, Eyes $450M+ in 2026 on Afrezza and FUROSCIX
MannKind (NASDAQ:MNKD) executives highlighted accelerating revenue growth, pipeline priorities, and commercialization plans during a discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, held following the company’s fourth-quarter and full-year 2025 earnings release. Oppenhei
MannKind Corporation (MNKD): A Bull Case Theory
We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation’s share was trading at $3.5000 as of February 25th. MNKD’s trailing and forward P/E were 49.91 and 34.36, respectively according to Yahoo Finance. MannKind Corporation, a biopharmaceutical company, focuses on the provision […]